2CARBONE P, KELLERHOUSE L, GEHAN E. Plasmacytic myeloma: a study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients[J]. A J M, 1967, 42(6): 937-948.
3COSTA G, ENGLE R L, SCHILLING A, a al. Melphalan and prednisone: an effective combination for the treatment of multiple myeloma[J]. AJM, 1973,54(4): 589-599.
4DURIE B G, SALMON S. A clinical staging system of multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival[J]. Cancer, 1975, 36(3):842-854.
5MERLINI G, WALDENSTROM I, JAYAKARS. A new improved clinical staging system for multiple myeloma based onthe analysis of 123 treated patients[J].Blood, 1980, 55(6):1011-1019.
6GREIPP P R, LUST J A, O'FALLON W M. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein inmultiple myeloma[J]. Blood, 1993, 82(11) : 3507-3508.
7SAN MIGUEL J F, GARCIA-SANZ R, GONZALEZ M. A new staging system for multiple myeloma based on the number of S-phase plasma cells[J]. Blood, 1995, 85(2) : 448-455.
8JACOBSON J L, HUSSEIN M A, BARLOGIE B. A new staging system for multiple myeloma patients based on the Southwest Oneology Group (SWOG) experience[J]. Br J Haematol, 2003, 122(3): 441-450.
9GREIPP P R, SAN MIGUEL G F, DURIE B G. A new international staging system(ISS) for multiple myeloma(MM)from the international myeloma working group[J]. Blood,2003, 102(11): 118.
109th International Workshop on Multiple Myeloma[J/OL]. from http://www.medseape.com/viewar tiele/458148 -- 2.Medseape hematology-oneologyhome,2003,6(2)/2003-07-31.
4Durie BGM, Salmon SE. A clinical staging system for multiple myeloma.Correlation of measured myeloma cell mass with presenting clinical features,response to treatment and survival. Cancer, 1975,36:842
5Greipp P R, San. Miguel G F, Durif B G. A new international staging system (ISS) for multiple myeloma(MM) from international Myeloma Working Group. J. Blood,2003,102(11 ): 118
6Byar D P. Identification of prognostic factors [A]. Buyse M E, Seaquet M J, Sylveter R S. Cancer Clinical trials. Methods and practice. England:Oxford University press. 1984,423
7Cuzick J, De Stavola BL, Cooper EH, et al. Long - term prognostic value of serum β2 microglobulin in myelomatosis. Br J Heamato 1990,175:506
8Greipp P R, Jesus San Miguel, Brian G. M. et al. International Staging System for multiple myeloma. J Clin Oncol.2005,23(15):3412
